Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: A system for assisting a rescuer includes: a chest compression sensor configured to sense movement of the patient's chest and a second sensor configured to sense information indicative of whether the rescuer's hand is in contact with or is not in contact with the patient's chest. The second sensor is configured to be positioned on the patient's chest at a location corresponding to a location of the rescuer's hand when delivering chest compressions to the patient's chest. The system also includes a feedback device and a computing unit. The computing unit is configured to cause the feedback device to provide chest compression feedback based on a determined chest compression rate and chest compression depth and to provide chest release feedback based on a determination of whether the rescuer is releasing the chest in between chest compressions.

Abstract: An external defibrillator comprising: a unit for providing electrical stimulation of a patient; a battery module that includes: a battery housing; a plurality of battery banks within the housing, each of the battery banks being electrically isolated from each of the other battery banks within the housing and having a total lithium content of less than an amount requiring special handling procedures during transportation and storage; and a plurality of pairs of electrical contacts external to the housing, each of the pairs of electrical contacts being configured to provide an electrical connection to an associated battery bank; and a connector unit external to the battery housing that includes: a plurality of pairs of electrical contacts configured to mate with the plurality of pairs of electrical contacts of the battery module; and circuitry electrically connecting the plurality of pairs of electrical contacts of the connector unit to provide a single voltage output to the unit for providing electrical stimul

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: The present invention provides a method for preparing an intermediate compound of sitagliptin represented by formula I. The preparation method comprises: dissolving a compound represented by formula II into an organic solvent; and under the catalysis of fatty acid and effect of chlorosilane, performing a reduction reaction of carbon-carbon double bonds, so as to obtain the intermediate compound of sitagliptin represented by formula I, R being methyl or formoxyl. The preparation method of the present invention avoids precious metal as a catalyst, and accordingly, the cost is low, the post-treatment is simple, the product has a high yield, chemical purity and optical purity, and de % is greater than 99.6%, and the preparation method can be used in synthesis of sitagliptin and is suitable for industrial production.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Systems, methods, and computer program products to perform an operation comprising receiving a user action script, a first callback queue, and an asynchronous operation queue generated based on a first execution instance of a web application, simulating the first execution instance of the web application, comprising: invoking a second execution instance of the web application, simulating each user action of a plurality of user actions specified in the user action script, based on a plurality of callback functions specified in the first callback queue, simulating each asynchronous operation of a plurality of asynchronous operations specified in the asynchronous operation queue based on the plurality of callback functions specified in the first callback queue, and generating a second callback queue based on the simulated plurality of user actions and asynchronous operations.

Abstract: A system for assisting a rescuer in performing resuscitation activities on a patient is provided. The system includes at least one chest compression sensor configured to sense movement of the patient's chest and a second sensor configured to sense information indicative of whether the rescuer's hand is in contact with or is not in contact with the patient's chest. The second sensor can be configured to be positioned on the patient's chest at a location corresponding to a location of the rescuer's hand when delivering chest compressions to the patient's chest. The system also includes a processor configured to: receive and process information from the chest compression sensor and the second sensor; identify occurrence of a chest compression based on information from the second sensor; and calculate chest compression depth based on the information sensed by the chest compression sensor during the identified chest compression.

Abstract: The invention discloses a novel quinazoline derivative LU1501 and a preparing method thereof, wherein the quinazoline derivative has a chemical name of N-[(4-fluorophenyl)methyl]-4-N-{7-methoxy-6-[(2-pyrrolidin-1-yl)hydroxyethyl]quinazoline-4-yl}phen-1,4-diamine. The quinazoline derivative and a pharmaceutically acceptable salt, a solvate and a hydrate thereof have excellent anti-tumor activity in vitro and in vivo to MCF-7, SK-BR-3, A549, HCT 116, U-118 MG, U-87 MG and MDA-MB-468, and have preferable application prospects on preparing anti-tumor drugs.

Abstract: The invention discloses a novel quinazoline derivative LU1501 and a preparing method thereof, wherein the quinazoline derivative has a chemical name of N-[(4-fluorophenyl)methyl]-4-N-{7-methoxy-6-[(2-pyrrolidin-1-yl)hydroxyethyl]quinazoline-4-yl}phen-1,4-diamine. The quinazoline derivative and a pharmaceutically acceptable salt, a solvate and a hydrate thereof have excellent anti-tumor activity in vitro and in vivo to MCF-7, SK-BR-3, A549, HCT 116, U-118 MG; U-87 MG and MDA-MB-468, and have preferable application prospects on preparing anti-tumor drugs.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.

Abstract: A computer-implemented method includes monitoring a template registry for changes in the template registry. In response to detecting a new template in the template registry, the method includes analyzing the new template to identify explicit and implicit metadata corresponding to the new template. The method further includes determining one or more possible link dependencies between a container based on the new template and one or more other containers, respectively, based on the identified explicit and implicit metadata. In addition, the method includes providing container setting recommendations to a user based on the one or more possible link dependencies and the identified explicit and implicit metadata.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: A system for assisting a rescuer in performing resuscitation activities on a patient is provided. The system includes at least one chest compression sensor configured to sense movement of the patient's chest and a second sensor configured to sense information indicative of whether the rescuer's hand is in contact with or is not in contact with the patient's chest. The second sensor can be configured to be positioned on the patient's chest at a location corresponding to a location of the rescuer's hand when delivering chest compressions to the patient's chest. The system also includes a processor configured to: receive and process information from the chest compression sensor and the second sensor; identify occurrence of a chest compression based on information from the second sensor; and calculate chest compression depth based on the information sensed by the chest compression sensor during the identified chest compression.